We are monitoring the impact of COVID-19 on Latin America Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Share on

Latin America Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1123
Pages: 133

Latin American Monoclonal Antibodies Market Size (2022 to 2027)

The size of the Latin American Monoclonal Antibodies Market is forecasted to be USD 4.88 Billion in 2022 and USD 7.69 billion by 2027, growing at a CAGR of 9.5% from 2022 to 2027.

MARKET DRIVERS:

There is great experience and development of monoclonal antibodies in Latin America, so there is great interest from local and foreign pharmaceutical companies to enter the market to research, produce and market locally and internationally. Moreover, increasing research collaborations to develop robust drug streamlining is a major factor that is expected to drive market growth over the forecast period.

The Latin American monoclonal antibodies market is expected to experience rapid growth in the coming years, mainly due to discovering new molecules. Therefore, biotech companies invest heavily in R&D to stay ahead of the monoclonal antibody market by constantly offering new innovative products.

There are a growing number of government initiatives and funding for clinical trials of drugs, which can be used in the treatment of Covid-19, which are expected to support market growth. For example, in 2020, the World Health Organization launched the “Solidarity” trial, a multinational initiative to test new and old drugs/therapies to treat Covid-19.

MARKET RESTRAINTS:

Despite the efforts of large multinationals to produce innovative biological drugs, the Latin American market for monoclonal antibodies is constantly evolving and remains competitive. Additionally, recent changes in local regulations positively affect the Latin American monoclonal antibodies market and fuel the race against innovative products.

Although current regulations allow the registration of generic versions of conventional pharmaceuticals, regulatory pathways for monoclonal antibody drugs are still unclear in some Latin American countries. In addition, in many Latin American countries, such as Brazil, Mexico, and Argentina, some insurers do not cover certain biological drug treatments. Therefore, patients have to buy the drug out of pocket or by monoclonal antibodies through the government. Thus, the lower the prices, the higher the sales in the public and private sectors.

The main challenges facing players in the Latin American monoclonal antibody market relate to the high costs of R&D and clinical trials required to demonstrate the efficacy and safety of the product, as well as the need to keep end prices low. Therefore, to expand their business, regional organic manufacturers are looking to license their products to global players.

Intellectual property is not protected in all Latin American countries, so that companies can register monoclonal antibodies against innovative biological drugs protected in other regions. Therefore, innovative companies compete with cheaper products with similar chemical structures, clearly at a disadvantage. In response, they are implementing competitive strategies to prevent monoclonal antibodies from entering the Latin American market.

This research report on the Latin American monoclonal antibodies market has been segmented & sub-segmented into the following categories:

By Source: 

  • Murine
  • Chimeric
  • Humanized
  • Human

By Indication: 

  • Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Others
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End-User: 

  • Hospitals/Clinics
  • Research Institute
  • Diagnostic Laboratories

By Application: 

  • Medical
  • Experimental
  • Western Blot
    • ELISA
    • Radioimmune Assays
    • Immunofluorescence
    • Others

By Country: 

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Regional Analysis

In Latin America, the Brazilian monoclonal antibodies market is forecasted to lead the market during the forecast period. Monoclonal antibodies in Latin America represent many pharmaceutical spending but a relatively small number of prescriptions. In many Latin American countries, monoclonal antibodies for breast cancer, rheumatoid arthritis, and non-small cell lung cancer are currently in development and may soon be on the market.

KEY MARKET PLAYERS:

A few prominent companies operating in the Latin American monoclonal antibodies market profiled in this report are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly, and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., and Biogen Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Latin America                            

                                6.1.1 Introduction           

                                6.1.2 Brazil         

                                6.1.3 Argentina

                                6.1.4 Mexico     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Seattle Genetics (U.S.)                          

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Biogen Inc.(U.S.)                      

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Monoclonal Antibodies Market By Murine, From 2022 - 2027 ( USD Billion )
  2. Latin America Chimeric Market By Region, From 2022 - 2027 ( USD Billion )
  3. Latin America Humanized Market By Region, From 2022 - 2027 ( USD Billion )
  4. Latin America Human Market By Region, From 2022 - 2027 ( USD Billion )
  5. Latin America Monoclonal Antibodies Market By Cancer, From 2022 - 2027 ( USD Billion )
  6. Latin America Autoimmune Diseases Market By Region, From 2022 - 2027 ( USD Billion )
  7. Latin America Infectious Diseases Market By Region, From 2022 - 2027 ( USD Billion )
  8. Latin America Cardiovascular Diseases Market By Region, From 2022 - 2027 ( USD Billion )
  9. Latin America CNS Disorders Market By Region, From 2022 - 2027 ( USD Billion )
  10. Latin America Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2022 - 2027 ( USD Billion )
  11. Latin America Monoclonal Antibodies Market By Hospitals/Clinics, From 2022 - 2027 ( USD Billion )
  12. Latin America Research Institute Market By Region, From 2022 - 2027 ( USD Billion )
  13. Latin America Diagnostic Laboratories Market By Region, From 2022 - 2027 ( USD Billion )
  14. Latin America Monoclonal Antibodies Market By Medical, From 2022 - 2027 ( USD Billion )
  15. Latin America Experimental Market By Region, From 2022 - 2027 ( USD Billion )
  16. Brazil Monoclonal Antibodies Market By Murine, From 2022 - 2027 ( USD Billion )
  17. Brazil Monoclonal Antibodies Market By Cancer, From 2022 - 2027 ( USD Billion )
  18. Brazil Monoclonal Antibodies Market By Hospitals/Clinics, From 2022 - 2027 ( USD Billion )
  19. Brazil Monoclonal Antibodies Market By Medical, From 2022 - 2027 ( USD Billion )
  20. Argentina Monoclonal Antibodies Market By Murine, From 2022 - 2027 ( USD Billion )
  21. Argentina Monoclonal Antibodies Market By Cancer, From 2022 - 2027 ( USD Billion )
  22. Argentina Monoclonal Antibodies Market By Hospitals/Clinics, From 2022 - 2027 ( USD Billion )
  23. Argentina Monoclonal Antibodies Market By Medical, From 2022 - 2027 ( USD Billion )
  24. Mexico Monoclonal Antibodies Market By Murine, From 2022 - 2027 ( USD Billion )
  25. Mexico Monoclonal Antibodies Market By Cancer, From 2022 - 2027 ( USD Billion )
  26. Mexico Monoclonal Antibodies Market By Hospitals/Clinics, From 2022 - 2027 ( USD Billion )
  27. Mexico Monoclonal Antibodies Market By Medical, From 2022 - 2027 ( USD Billion )
  28. Latin America Monoclonal Antibodies Market By Blood Cancer, From 2022 - 2027 ( USD Billion )
  29. Latin America Breast Cancer Market By Region, From 2022 - 2027 ( USD Billion )
  30. Latin America Colorectal Cancer Market By Region, From 2022 - 2027 ( USD Billion )
  31. Latin America Lung Cancer Market By Region, From 2022 - 2027 ( USD Billion )
  32. Latin America Pancreatic Cancer Market By Region, From 2022 - 2027 ( USD Billion )
  33. Latin America Others Market By Region, From 2022 - 2027 ( USD Billion )
  34. Brazil Monoclonal Antibodies Market By Blood Cancer, From 2022 - 2027 ( USD Billion )
  35. Argentina Monoclonal Antibodies Market By Blood Cancer, From 2022 - 2027 ( USD Billion )
  36. Mexico Monoclonal Antibodies Market By Blood Cancer, From 2022 - 2027 ( USD Billion )
  37. Latin America Monoclonal Antibodies Market By Western Blot, From 2022 - 2027 ( USD Billion )
  38. Latin America ELISA Market By Region, From 2022 - 2027 ( USD Billion )
  39. Latin America Radioimmune Assays Market By Region, From 2022 - 2027 ( USD Billion )
  40. Latin America Immunofluorescence Market By Region, From 2022 - 2027 ( USD Billion )
  41. Latin America Others Market By Region, From 2022 - 2027 ( USD Billion )
  42. Brazil Monoclonal Antibodies Market By Western Blot, From 2022 - 2027 ( USD Billion )
  43. Argentina Monoclonal Antibodies Market By Western Blot, From 2022 - 2027 ( USD Billion )
  44. Mexico Monoclonal Antibodies Market By Western Blot, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample